Currently Viewing:
Newsroom
Currently Reading
FDA Issues New Draft Guidance on T2D Medication Safety Trials
March 09, 2020 – Gianna Melillo
AJMC® in the Press, March 6, 2020
March 06, 2020 – AJMC Staff
AJMC® in the Press, February 28, 2020
February 28, 2020 – AJMC Staff
Canagliflozin Conveys Lower Risk of Adverse CV Events in Patients With High CV Risk, T2D
February 27, 2020 – Maggie L. Shaw
FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD
February 24, 2020 – Gianna Melillo
This Week in Managed Care: February 21, 2020
February 21, 2020
Improving Cardiovascular Outcomes Among Patients With Type 2 Diabetes: An Interview With Nihar Desai, MD, MPH
February 20, 2020
6 Connected Patient Challenge Finalists to Compete in Live Pitch-Off
February 18, 2020 – Samara Rosenfeld
Statins Significantly Reduce Risk of Hospitalized Exacerbations in Patients With COPD
February 17, 2020 – Matthew Gavidia

FDA Issues New Draft Guidance on T2D Medication Safety Trials

Gianna Melillo
The FDA announced a new draft guidance to consider broader evaluations beyond cardiovascular outcomes trials for type 2 diabetes (T2D) medications.
 
The FDA announced a new draft guidance to consider broader evaluations beyond cardiovascular outcomes trails for type 2 diabetes (T2D) medications.

The guidance entitled, “Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control,” aims to solicit public comment on proposals for broad safety evaluations prior to drug approvals. In addition to patients with cardiovascular disease, the guidelines single out older patients and those with chronic kidney disease who may be vulnerable to drug-related side effects.

The relationship between cardiovascular disease, kidney disease, and diabetes has been well-documented and researchers have found chronic kidney disease may even be a cause of diabetes. Patients with T2D also suffer from serious medical complications and comorbidities, such as nerve damage, kidney and eye damage, sleep apnea, and heart and blood vessel disease.

However, the new draft guidance does not recommend sponsors of all new therapies for T2D “uniformly rule out a specific degree of risk for ischemic cardiovascular adverse outcomes,” recommended in previous guidance.

The new draft replaces 2 previous industry guidances, both published in 2008: “Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes,” and “Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention.”

The decision comes after the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee noted the need for safety data beyond that of cardiovascular safety is required to evaluate antidiabetic drugs before they are approved.

“By following previous FDA recommendations, sponsors have shown that new T2D drugs do not have excess ischemic cardiovascular risk, which has provided reassuring cardiovascular safety information for millions of diabetes patients,” said Lisa Yanoff, MD, acting director of the FDA’s division for metabolism and endocrinology products. “Now, with this proposed approach, we will have broader, valuable safety information for these medications.”

Currently, over 30 million Americans have diabetes, and 90% to 95% of that population have T2D.

Related Articles

Big Data and CVD Benefits of Anti-Diabetes Medications
First Nations Women of Canada Have Higher Diabetes Rates, Study Finds
SGLT2 Inhibitors Benefit All Patients with T2D, Regardless of CVD Diagnosis
FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD
Abbott, DexCom Partner With Insulet to Improve Diabetes Management Technology
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up